CX-4945 sodium saltCAS# 1309357-15-0 |
- XL413
Catalog No.:BCC4241
CAS No.:1169558-38-6
- XL413 hydrochloride
Catalog No.:BCC4039
CAS No.:1169562-71-3
- TBB
Catalog No.:BCC1988
CAS No.:17374-26-4
- TTP 22
Catalog No.:BCC2017
CAS No.:329907-28-0
- Ellagic acid
Catalog No.:BCN5533
CAS No.:476-66-4
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 1309357-15-0 | SDF | Download SDF |
PubChem ID | 49788959 | Appearance | Powder |
Formula | C19H11ClN3NaO2 | M.Wt | 371.75 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Synonyms | Silmitasertib sodium salt | ||
Solubility | H2O : 16.67 mg/mL (44.84 mM; Need ultrasonic) DMSO : 6.67 mg/mL (17.94 mM; Need ultrasonic) | ||
Chemical Name | sodium;5-(3-chloroanilino)benzo[c][2,6]naphthyridine-8-carboxylate | ||
SMILES | C1=CC(=CC(=C1)Cl)NC2=C3C=CN=CC3=C4C=CC(=CC4=N2)C(=O)[O-].[Na+] | ||
Standard InChIKey | ODDAAPQSODILSN-UHFFFAOYSA-M | ||
Standard InChI | InChI=1S/C19H12ClN3O2.Na/c20-12-2-1-3-13(9-12)22-18-15-6-7-21-10-16(15)14-5-4-11(19(24)25)8-17(14)23-18;/h1-10H,(H,22,23)(H,24,25);/q;+1/p-1 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
CX-4945 sodium salt Dilution Calculator
CX-4945 sodium salt Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 2.69 mL | 13.4499 mL | 26.8998 mL | 53.7996 mL | 67.2495 mL |
5 mM | 0.538 mL | 2.69 mL | 5.38 mL | 10.7599 mL | 13.4499 mL |
10 mM | 0.269 mL | 1.345 mL | 2.69 mL | 5.38 mL | 6.7249 mL |
50 mM | 0.0538 mL | 0.269 mL | 0.538 mL | 1.076 mL | 1.345 mL |
100 mM | 0.0269 mL | 0.1345 mL | 0.269 mL | 0.538 mL | 0.6725 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
CX-4945 sodium salt is an orally bioavailable, highly selective and potent CK2 inhibitor, with IC50 values of 1 nM against CK2α and CK2α'.
In Vitro:CX-4945 causes cell-cycle arrest and selectively induces apoptosis in cancer cells relative to normal cells, attenuates PI3K/Akt signalingand, and the antiproliferative activity of CX-4945 is correlated with expression levels of the CK2α catalytic subunit, Attenuation of PI3K/Akt signaling[1]. CX-4945 with bortezomib treatment prevents leukemic cells from engaging a functional UPR in order to buffer the bortezomib-mediated proteotoxic stress in ER lumen, and decreases pro-survival ER chaperon BIP/Grp78 expression[2]. CX-4945 induces cytotoxicity and apoptosis, and exerts anti-proliferative effects in hematological tumors by downregulating CK2 expression and suppressing activation of CK2-mediated PI3K/Akt/mTOR signaling pathways[3].
In Vivo:CX-4945 (25 or 75 mg/kg, p.o.) is well tolerated and demonstrated robust antitumor activity with concomitant reductions of the mechanism-based biomarker phospho-p21 (T145) in murine xenograft models[1].
References:
[1]. Siddiqui-Jain A, et al. CX-4945, an orally bioavailable selective inhibitor of protein kinase CK2, inhibits prosurvival and angiogenic signaling and exhibits antitumor efficacy. Cancer Res. 2010 Dec 15;70(24):10288-98.
[2]. Buontempo F, et al. Synergistic cytotoxic effects of bortezomib and CK2 inhibitor CX-4945 in acute lymphoblastic leukemia: turning off the prosurvival ER chaperone BIP/Grp78 and turning on the pro-apoptotic NF-κB. Oncotarget. 2016 Jan 12;7(2):1323-40.
[3]. Chon HJ, et al. The casein kinase 2 inhibitor, CX-4945, as an anti-cancer drug in treatment of human hematological malignancies. Front Pharmacol. 2015 Mar 31;6:70.
[4]. Kendall JJ, et al. CK2 blockade causes MPNST cell apoptosis and promotes degradation of β-catenin. Oncotarget. 2016 Aug 16;7(33):53191-53203.
- Entacapone
Catalog No.:BCC2217
CAS No.:130929-57-6
- 7-O-Acetylneocaesalpin N
Catalog No.:BCN7332
CAS No.:1309079-08-0
- N4-Benzoylcytidine
Catalog No.:BCC9072
CAS No.:13089-48-0
- Fmoc-Val-OSu
Catalog No.:BCC3572
CAS No.:130878-68-1
- 1beta,10beta-Epoxydehydroleucodin
Catalog No.:BCN7331
CAS No.:130858-00-3
- ent-kaurane-3,16,17-triol
Catalog No.:BCN6164
CAS No.:130855-22-0
- Decursinol angelate
Catalog No.:BCC9222
CAS No.:130848-06-5
- Scoparinol
Catalog No.:BCN6163
CAS No.:130838-00-5
- 7-Oxohinokinin
Catalog No.:BCN6162
CAS No.:130837-92-2
- Pseudolarifuroic acid
Catalog No.:BCN8048
CAS No.:130825-79-5
- Sipatrigine
Catalog No.:BCC7847
CAS No.:130800-90-7
- MDL-29951
Catalog No.:BCC4059
CAS No.:130798-51-5
- Cerberic acid B
Catalog No.:BCN4715
CAS No.:1309362-77-3
- GPR40 Activator 1
Catalog No.:BCC4125
CAS No.:1309435-60-6
- K145
Catalog No.:BCC4305
CAS No.:1309444-75-4
- Wittifuran X
Catalog No.:BCN4794
CAS No.:1309478-07-6
- Marumoside A
Catalog No.:BCN7702
CAS No.:1309604-34-9
- H 89 2HCl
Catalog No.:BCC4997
CAS No.:130964-39-5
- (±)-CPSI 1306
Catalog No.:BCC6161
CAS No.:1309793-47-2
- Sephin1
Catalog No.:BCC3980
CAS No.:13098-73-2
- MRS 4062 triethylammonium salt
Catalog No.:BCC6134
CAS No.:1309871-50-8
- 15-Methoxymkapwanin
Catalog No.:BCN6498
CAS No.:1309920-99-7
- VU 0360172 hydrochloride
Catalog No.:BCC6141
CAS No.:1309976-62-2
- alpha-Yohimbine
Catalog No.:BCN6166
CAS No.:131-03-3